BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Innovations | Nov 21, 2019
Targets & Mechanisms

Genocea's cautionary tale: avoid inhibitory neoantigens in vaccines

Genocea’s SITC presentations bolstered its case for screening out inhibitory neoantigens from cancer vaccines by suggesting the peptides play a role in checkpoint inhibitor resistance and promote disease progression. One of the keys to designing...
BC Innovations | Oct 11, 2019
Product Development

What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space. Over a dozen companies have launched programs to...
BioCentury | Sep 27, 2019
Product Development

Reading into the first wave of neoantigen results

The first clinical data from neoantigen vaccine companies have started to answer questions about the best way to quickly gauge whether patients are responding. The lessons include how to design combination trials that point to...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Extra | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's second round of Quick Takes on selected abstracts (see "May 15 ASCO...
BC Week In Review | Feb 15, 2019
Financial News

Genocea planning $39M financing

Genocea Biosciences Inc. (NASDAQ:GNCA) proposed to raise $39.2 million on Feb. 12 in a private placement from existing and new investors, through two closings. In the first, the company aims to raise $15 million by...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BC Week In Review | Sep 29, 2017
Clinical News

Genocea discontinues HSV-2 candidate GEN-003

Genocea Biosciences Inc. (NASDAQ:GNCA) said it is "exploring strategic alternatives" and ceasing development of GEN-003, which has completed Phase II testing to treat genital herpes simplex virus type 2 (HSV-2) infection. The company will reduce...
BC Innovations | Aug 24, 2017
Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
Items per page:
1 - 10 of 99
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Innovations | Nov 21, 2019
Targets & Mechanisms

Genocea's cautionary tale: avoid inhibitory neoantigens in vaccines

Genocea’s SITC presentations bolstered its case for screening out inhibitory neoantigens from cancer vaccines by suggesting the peptides play a role in checkpoint inhibitor resistance and promote disease progression. One of the keys to designing...
BC Innovations | Oct 11, 2019
Product Development

What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space. Over a dozen companies have launched programs to...
BioCentury | Sep 27, 2019
Product Development

Reading into the first wave of neoantigen results

The first clinical data from neoantigen vaccine companies have started to answer questions about the best way to quickly gauge whether patients are responding. The lessons include how to design combination trials that point to...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Extra | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's second round of Quick Takes on selected abstracts (see "May 15 ASCO...
BC Week In Review | Feb 15, 2019
Financial News

Genocea planning $39M financing

Genocea Biosciences Inc. (NASDAQ:GNCA) proposed to raise $39.2 million on Feb. 12 in a private placement from existing and new investors, through two closings. In the first, the company aims to raise $15 million by...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BC Week In Review | Sep 29, 2017
Clinical News

Genocea discontinues HSV-2 candidate GEN-003

Genocea Biosciences Inc. (NASDAQ:GNCA) said it is "exploring strategic alternatives" and ceasing development of GEN-003, which has completed Phase II testing to treat genital herpes simplex virus type 2 (HSV-2) infection. The company will reduce...
BC Innovations | Aug 24, 2017
Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
Items per page:
1 - 10 of 99